Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Immunotherapy is used to treat melanoma, however patient responses vary widely highlighting the need for factors that can predict therapeutic success. Here, the authors show that MHC-II molecules expressed by tumour cells are positively correlated with a good response to therapy and overall patient...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Douglas B. Johnson, Monica V. Estrada, Roberto Salgado, Violeta Sanchez, Deon B. Doxie, Susan R. Opalenik, Anna E. Vilgelm, Emily Feld, Adam S. Johnson, Allison R. Greenplate, Melinda E. Sanders, Christine M. Lovly, Dennie T. Frederick, Mark C. Kelley, Ann Richmond, Jonathan M. Irish, Yu Shyr, Ryan J. Sullivan, Igor Puzanov, Jeffrey A. Sosman, Justin M. Balko
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/459810ce61c5459985557e37a55f8eed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:459810ce61c5459985557e37a55f8eed
record_format	dspace
spelling	oai:doaj.org-article:459810ce61c5459985557e37a55f8eed2021-12-02T14:38:33ZMelanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy10.1038/ncomms105822041-1723https://doaj.org/article/459810ce61c5459985557e37a55f8eed2016-01-01T00:00:00Zhttps://doi.org/10.1038/ncomms10582https://doaj.org/toc/2041-1723Immunotherapy is used to treat melanoma, however patient responses vary widely highlighting the need for factors that can predict therapeutic success. Here, the authors show that MHC-II molecules expressed by tumour cells are positively correlated with a good response to therapy and overall patient survival.Douglas B. JohnsonMonica V. EstradaRoberto SalgadoVioleta SanchezDeon B. DoxieSusan R. OpalenikAnna E. VilgelmEmily FeldAdam S. JohnsonAllison R. GreenplateMelinda E. SandersChristine M. LovlyDennie T. FrederickMark C. KelleyAnn RichmondJonathan M. IrishYu ShyrRyan J. SullivanIgor PuzanovJeffrey A. SosmanJustin M. BalkoNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Douglas B. Johnson Monica V. Estrada Roberto Salgado Violeta Sanchez Deon B. Doxie Susan R. Opalenik Anna E. Vilgelm Emily Feld Adam S. Johnson Allison R. Greenplate Melinda E. Sanders Christine M. Lovly Dennie T. Frederick Mark C. Kelley Ann Richmond Jonathan M. Irish Yu Shyr Ryan J. Sullivan Igor Puzanov Jeffrey A. Sosman Justin M. Balko Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
description	Immunotherapy is used to treat melanoma, however patient responses vary widely highlighting the need for factors that can predict therapeutic success. Here, the authors show that MHC-II molecules expressed by tumour cells are positively correlated with a good response to therapy and overall patient survival.
format	article
author	Douglas B. Johnson Monica V. Estrada Roberto Salgado Violeta Sanchez Deon B. Doxie Susan R. Opalenik Anna E. Vilgelm Emily Feld Adam S. Johnson Allison R. Greenplate Melinda E. Sanders Christine M. Lovly Dennie T. Frederick Mark C. Kelley Ann Richmond Jonathan M. Irish Yu Shyr Ryan J. Sullivan Igor Puzanov Jeffrey A. Sosman Justin M. Balko
author_facet	Douglas B. Johnson Monica V. Estrada Roberto Salgado Violeta Sanchez Deon B. Doxie Susan R. Opalenik Anna E. Vilgelm Emily Feld Adam S. Johnson Allison R. Greenplate Melinda E. Sanders Christine M. Lovly Dennie T. Frederick Mark C. Kelley Ann Richmond Jonathan M. Irish Yu Shyr Ryan J. Sullivan Igor Puzanov Jeffrey A. Sosman Justin M. Balko
author_sort	Douglas B. Johnson
title	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
title_short	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
title_full	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
title_fullStr	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
title_full_unstemmed	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
title_sort	melanoma-specific mhc-ii expression represents a tumour-autonomous phenotype and predicts response to anti-pd-1/pd-l1 therapy
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/459810ce61c5459985557e37a55f8eed
work_keys_str_mv	AT douglasbjohnson melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT monicavestrada melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT robertosalgado melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT violetasanchez melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT deonbdoxie melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT susanropalenik melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT annaevilgelm melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT emilyfeld melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT adamsjohnson melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT allisonrgreenplate melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT melindaesanders melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT christinemlovly melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT dennietfrederick melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT markckelley melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT annrichmond melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT jonathanmirish melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT yushyr melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT ryanjsullivan melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT igorpuzanov melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT jeffreyasosman melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy AT justinmbalko melanomaspecificmhciiexpressionrepresentsatumourautonomousphenotypeandpredictsresponsetoantipd1pdl1therapy
_version_	1718390946552348672

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Ejemplares similares